Sign In
Section Navigation
Common TitleTMC125-C227
Official Title A Phase II, Randomized, Active Controlled, Open Label Trial to Investigate the Efficacy and Tolerability of Etravirine (TMC125) in HIV-1 Infected Subjects, Who Are PI-naive and With Documented Genotypic Evidence of NNRTI Resistance From Previous NNRTI Use.
Phase Phase II
ClinicalTrials.gov NCT00225303
Treatments
Etravirine
Etravirine Intelence

Etravirine

Tradename:IntelenceOther Names:ETRClass:Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)
Categories Treatment-Experienced
Funding
IndustryTibotec Pharmaceuticals, Ireland
References
  • Ruxrungtham K, Pedro RJ, Latiff GH, et al. Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227. HIV Med. 2008;9:883-96.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.